Across TCGA pan-cancer cohorts, PRAMEF15 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRAMEF15 data layer compared with 10 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRAMEF15 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF15 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, OV, and ESCA are the cancer types where PRAMEF15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.128	0.695	.002	24	view →
OV	OS	Median	III,IV	0.082	0.837	<.001	20	view →
ESCA	DFS	Median	III,IV	0.100	0.442	.003	18	view →
SKCM	OS	Median	All	1.000	0.866	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PRAMEF15 tumor-vs-normal RNA expression · all PRAMEF15 data types